A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
← catalyst calendarNCT06305234 · readout in 2,648 d
Sponsored by BioMarin Pharmaceutical (industry) · BMRN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-20 | actual | When the study began enrolling |
| Primary completion | 2033-11-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-11-18 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Phenylketonuria (PKU)
Intervention
- Drug: Pegvaliase
Primary outcome
what the primary-completion date above is the date OFTo evaluate immunologic and inflammatory responses associated with occurrences of
measured A maximum of 10 years treatment duration.
Permalink · BMRN's whole pipeline · Catalyst calendar · Every registered study · What changed